Recurrent Carcinoid Valvulopathy after Bioprosthetic Valve Surgery Abstract #1021

Introduction: Carcinoid heart disease (CHD) typically affects right-sided cardiac structures causing leaflet thickening, retraction and valve dysfunction requiring surgery.
Aim(s): Evaluate early prosthetic dysfunction after valve replacement (VR) with tissue valves.
Materials and methods: From Jan 2001 to Nov 2013, 27 consecutive patients with carcinoid syndrome, liver metastases and CHD had tricuspid or/and pulmonic valve replacement with tissue valves. Retrospective analysis of prospectively collected clinical, laboratory and echo data was performed. We could not assess recurrence in six patients due to perioperative mortality (n:3; 11%), valve replacement in 2013 (N:2), lost follow-up (n:1).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Asst. Clin. Prof Jerome S Zacks

To read results and conclusion, please login ...

Further abstracts you may be interested in

#104 Myocardial motion abnormalities in patients with carcinoid disease without overt carcinoid heart disease
Introduction: Cardiac abnormalities occur in 15-70% of patients with carcinoid disease, typified by fibrosis of the right-sided valves. Myocardial motion abnormalities in subjects without overt carcinoid heart disease have not been previously described. Tissue Doppler Imaging (TDI) allows quantative analysis of myocardial motion. We used this technique to investigate whether myocardial motion is reduced, suggesting fibrosis, in patients with carcinoid disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Christopher Wong
#261 Recognizing Carcinoid Heart Disease and Timing of Cardiac and Abdominal Procedures
Introduction: Recognition of right heart failure in Carcinoid Heart Disease enables a decision to be made concerning the proper timing of Cardiac and abdominal tumor-reductive surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jerome S Zacks
Authors: Zacks J, Shafir M, Castillo J, Choi J, ...
#1272 Telotristat Etiprate Appears to Halt Carcinoid Heart Disease
Introduction: Carcinoid Heart Disease (CHD) is a serious complication of the Carcinoid Syndrome (in as many as 50% of patients during the course of their disease). 46% of cases operated with bioprosthetic valves develop recurrent carcinoid valvulopathy on the newly implanted tissue valves. Until now, only mechanical prosthetic valves avoid recurrent fibrosis.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Others
Presenting Author: MD, FACC, FCCP Jerome Zacks
Authors: Zacks J, Lavine R, Ratner L, Warner R, ...
#1762 Prevalence of Carcinoid Heart Disease in Patients with Disseminated Small Intestinal NET
Introduction: In patients with small intestinal neuroendocrine tumours (SI-NETs), serotonin may induce fibrosis and lead to carcinoid heart disease (CHD) with right sided valvular dysfunction.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, PhD Gitte Dam
#1941 Integrated Safety Analysis of Telotristat Ethyl in Patients with Carcinoid Heart Disease
Introduction: Release of serotonin by neuroendocrine tumors is associated with carcinoid heart disease (CaHD), which may pose challenges for carcinoid syndrome (CS) treatment.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Pablo Lapuerta
Authors: Lapuerta P, Kulke M H, Pavel M, Biran T, ...
Keywords: serotonin, 5-HIAA